X4 Pharmaceuticals Inc  (XFOR)

News about X4 Pharmaceuticals Inc

Empowering Innovation: X4 Pharmaceuticals Attracts Top Talent with Inducement Awards
Jun 03 2024
X4 Pharmaceuticals Continues to Attract Top Talent with Inducement AwardsIn a move to further strengthen its team of experts dedicated to improvi...

Exciting New Findings from X4 Pharmaceuticals Ongoing Phase 2 Trial in Chronic Neutrop...
May 29 2024
In the world of pharmaceutical sciences, breakthrough clinical data from ongoing trials is always eagerly awaited. X4 Pharmaceuticals is set to host a...

X4 Pharmaceuticals Announces $125 Million Capital Infusion to Extend Cash Runway, Driving Growth and Innovation in Biopharmaceuticals Industry
May 09 2024
X4 Pharmaceuticals Secures $125 Million Non-Dilutive Capital to Extend Cash Runway into Late 2025X4 Pharmaceuticals Inc. recently announced a maj...

X4 Pharmaceuticals Grants Inducement Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 01 2024
X4 Pharmaceuticals, a renowned company dedicated to enhancing the lives of individuals with rare immune system diseases, has recently announ...

X4 Pharmaceuticals Empowers New Employees to Drive Rare Disease Research Advancements
Apr 02 2024
X4 Pharmaceuticals Grants Inducement Awards to New Employees to Drive Innovation in Rare Disease ResearchBOSTON, April 02, 2024 - X4 Pharmaceutic...

X4 Pharmaceuticals Advances Mavorixafor into Pivotal Phase 3 Trial for Chronic Neutropenia Treatment, Sets Sights on Transforming Patient Outcomes
Dec 09 2023
X4 Pharmaceuticals, a renowned biopharmaceutical company, recently presented additional data from the Phase 2 trial of their drug, Mavorixaf...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 04 2023

X4 Pharmaceuticals Inc Reveals Jaw-Dropping $-27.214 Million Operating Shortfall in Latest Report
Nov 12 2023
As the July to September 30 2023 reporting season continues, the stock market has been buzzing with updates from various companies. Among them, the Bi...

XFOR*s Financial Strain Continues to Grow as Operating Shortfall Soars to $-25.805 Million in Q2 2023
Aug 11 2023
IntroductionAs we delve into the financial performance of X4 Pharmaceuticals Inc during the April to June 30, 2023 reporting season, shareho...

X4 Pharmaceuticals Inc Sees Rising Working Costs, Despite Positive Momentum in ROI Rankings
May 05 2023
X4 Pharmaceuticals Inc, a growing player in the biotechnology and pharmaceuticals sector, recently released its financial results for the 12 months en...

The arising company from the Biotechnology & Pharmaceuticals market the XFOR published the fiscal fourth quarter of 2022, numbers
May 05 2023

The arising corporation from the Biotechnology & Pharmaceuticals market the XFOR released the financial second quarter of 2022, numbers
May 05 2023


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com